Bruce Greenberg Email

VP Finance, Interim CFO, and Treasurer . Aldeyra Therandshy;aandshy;peuandshy;tics

Current Roles

Employees:
23
Revenue:
$3.6M
About
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.
Aldeyra Therandshy;aandshy;peuandshy;tics Address
131 Hartwell Avenue
Lexington, null
Aldeyra Therandshy;aandshy;peuandshy;tics Email
Aldeyra Therandshy;aandshy;peuandshy;tics Phone Numbers
781-761-4904

Past Companies

Aldeyra TherapeuticsSenior Vice President of Finance, Interim CFO, and Treasurer
Aldeyra TherapeuticsVice President, Controller
Karyopharm Therapeutics Inc.Corporate Controller

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.